Clinical trial
Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
NCT00065468 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00065468 |
|---|---|
| Title | Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma |
| Official title | A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma. |
| Acronym | ARCC |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell, Kidney Neoplasms |
| Intervention type | Drug |
| Interventions | Interferon Alfa, CCI-779, Interferon Alfa and CCI-779 |
| Enrollment | 626 |
| Start date | Jul 1, 2003 |
| Primary completion | Jun 1, 2006 |
| Completion | Mar 1, 2011 |
| First posted | Jul 25, 2003 |
| Last update posted | Oct 25, 2012 |
| Countries | Argentina, Australia, Canada, Czechia, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Mexico, Netherlands and 13 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: